A nuclear receptor corepressor modulates transcriptional activity of antagonist-occupied steroid hormone receptor

Molecular Endocrinology

Volumn 12, Issue 4, 1998, Pages 513-524

  Zhang, Xun ^b   Jeyakumar, M ^a   Petukhov, Sergei ^a   Bagchi, Milan K ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; CELL NUCLEUS RECEPTOR; ESTROGEN; MIFEPRISTONE; PROGESTERONE; STEROID HORMONE ANTAGONIST;

ARTICLE; COMPETITIVE INHIBITION; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; REGULATOR GENE; REPRESSOR GENE; TRANSCRIPTION REGULATION;

EID: 0032230289     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/mend.12.4.0089     Document Type: Article

References (51)

1. The steroid and thyroid hormone receptor superfamily
2. Molecular mechanisms of action of steroid/thyroid receptor superfamily members
3. The nuclear receptor superfamily: The second decade
4. Steroid hormone receptors: Many actors in search of a plot
5. Nuclear receptor coactivators and corepressors
6. Protein encoded by v-erbA functions as a thyroid hormone receptor antagonist
7. Thyroid hormone aporeceptor represses T 3 inducible promoters and blocks activity of the retinoic acid receptor
8. A transferable silencing domain is present in the thyroid hormone receptor, in the v-erbA oncogene product and in the retinoic acid receptor
9. Functional evidence for ligand-dependent dissociation of thyroid hormone and retinoic acid receptors from an inhibitory cellular factor
10. The τ-4 activation domain of the thyroid hormone receptor is required for release of a putative corepressor(s) necessary for transcriptional silencing
11. Transcriptional silencing by unliganded thyroid hormone receptor β requires a soluble corepressor that interacts with the ligand-binding domain of the receptor
12. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor
13. Polarity-specific activities of retinoic acid receptors determined by a co-repressor
14. A transcriptional co-repressor that interacts with nuclear hormone receptors
15. 3 receptor-associating cofactors), a family of cofactors that associate with, and modulate the activity of, nuclear hormone receptors
16. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily
17. TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors
18. ACBP integrator complex mediates transcriptional activation and AP- 1 inhibition by nuclear receptors
19. Analysis of the functional role of steroid receptor coactivator-1 in ligand-induced transactivation by thyroid hormone receptor
20. A nuclear hormone receptor corepressor mediates trancriptional silencing by receptors with distinct repression domains
21. A complex containing NCoR, mSin 3 and histone deacetylase mediates transcriptional repression
22. Common non-hormone binding component in nontransformed chick oviduct receptors of four steroid hormones
23. Contragestion and other clinical applications of RU486, an antiprogesterone at the receptor
24. Agonistic and antagonistic activities of RU 486 on the functions of the human progesterone receptor
25. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the antioestrogen 4-hydroxytamoxifen
26. The molecular biology of RU 486. Is there a role for antiprogestins in the treatment of breast cancer?
27. Receptors bound to antiprogestin form abortive complexes with hormone responsive elements
28. Identification of a functional intermediate in receptor activation in progesterone-dependent cell-free transcription
29. Progesterone enhances gene transcription by receptor free of heat shock proteins hsp90, hsp56, and hsp 70
30. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions
31. Antagonist-occupied human progesterone receptors bound to DNA are functionally switched to transcriptional agonists by cAMP
32. The progesterone antagonist RU 486 acquires agonist activity upon stimulation of cAMP signaling path-ways
33. Alterations in the agonist/antagonist balance of antiestrogens by activation of protein kinase A signaling pathways in breast cancer cells: Antiestrogen selectivity and promoter dependence
34. Modulation by vitamin B 6 of glucocorticoid receptor-mediated gene expression requires transcription factors in addition to the glucocorticoid receptor
35. The extreme C-terminus of progesterone receptor conrains a transcriptional repressor domain that functions through a putative corepressor
36. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain binding coactivator L7/SPA and the corepressor NCoR or SMRT
37. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen
38. The mechanism of RU 486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor
39. Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation
40. SMRT isoforms mediate repression and anti-repression of nuclear receptor heterodimers
41. Transcription activation by estrogen and progesterone receptors
42. The human estrogen receptor has two independent nonacidic transcriptional activation functions
43. A third transactivation function (AF3) of human progesterone receptors located in the unique N-terminal segment of the B-isoform
44. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase
45. Two types of antiprogestins identified by their differential action in transcriptionally active extracts from T47D cells
46. Ligand modulates the interaction of thyroid hormone receptor β with the basal transcription machinery
47. Unliganded thyroid hormone receptor a can target TATA-binding protein for transcriptional repression
48. When tamoxifen turns bad
49. Endocrine pharmacology of antiestrogens as antitumor agents
50. Ligand-dependent cross-talk between steroid and thyroid hormone receptors